Rodent carcinogenicity of peroxisome proliferators and issues on human relevance

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 22, Issue 1, 2004, Pages 37-55

  Lai, David Y ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Hepatocarcinogenesis; Human relevance; Peroxisome proliferators; PPAR alpha

Indexed keywords

ENVIRONMENTAL ENGINEERING; PESTICIDES; PLASTICIZERS; SOLVENTS; TUMORS;

MONKEYS; PEROXISOME PROLIFERATORS (PP); RODENT;

CARCINOGENS;

ANTILIPEMIC AGENT; CARCINOGEN; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PESTICIDE; PHTHALIC ACID ESTER; PLASTICIZER; SOLVENT;

ADSORPTION KINETICS; CANCER EPIDEMIOLOGY; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; DOSE RESPONSE; DRUG MECHANISM; GUINEA PIG; HAMSTER; HEPATOMEGALY; LIVER CANCER; LIVER CARCINOGENESIS; LIVER TUMOR; LONG TERM EXPOSURE; MONKEY; MOUSE; NONHUMAN; PEROXISOME; PHARMACODYNAMICS; RAT; REVIEW; RODENT; SPECIES DIFFERENCE; STATISTICAL SIGNIFICANCE;

ANIMALS; EPIDEMIOLOGIC STUDIES; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PEROXISOME PROLIFERATORS; PPAR ALPHA; RATS; RISK ASSESSMENT; SPECIES SPECIFICITY;

ANIMALIA; CAVIA; CAVIA PORCELLUS; CRICETINAE; RODENTIA; SUS SCROFA;

EID: 3042517028     PISSN: 10590501     EISSN: None     Source Type: Journal    
DOI: 10.1081/GNC-120038005     Document Type: Review

References (62)

1. Stott WT. Chemically induced proliferation of peroxisome: implications for risk assessment. Regul Toxicol Pharmacol 1988; 8:125-159.
2. Bentley P, Calder I, Elcombe C, Grasso P, Stringer D, Wiegand H-J. Hepatic peroxisome proliferation in rodents and its significance for humans. Fd Chem Tox 1993; 31:857-907.
3. Lake BG, Evans JG, Gray TJB, Korosi SA, North CJ. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol Appl Pharmacol 1989; 99:148.
4. Lake BG, Rumsby PC, Price RJ, Cunningham ME. Species differences in hepatic peroxisome proliferation cell replication and transforming growth factor-β-1 gene expression in the rat, Syrian hamster and guinea pig. Mutat Res 2000, 448(2):213-225.
5. Hanefeld M, Kemmer C, Kadner E. Relationship between morphorlogical changes and lipid lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 1983; 46:239-246.
6. Moody DE, Reddy JK, Lake BG, Popp JA, Reese DH. Peroxisome proliferation and non-genotoxic carcinogenesis: commentary on a symposium. Fund Appl Toxicol 1991; 16:233-248.
7. Reddy JK, Lalwai ND. Carcinogenesis by hepatic peroxisome proliferators. Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit Rev Toxicol 1983; 12:1-58.
8. Moody DE, Reddy JK. Hepatic peroxisome (microbody) proliferation in rats fed plasticizers and related compounds. Toxicol Appl Pharmacol 1978; 45:497-504.
9. Kluwe WM, Huff JE, Matthews HB, Irwin R, Haseman JK. Comparative chronic toxicities and carcinogenic potentials of 2-ethylhexyl-containing compounds in rats and mice. Carcinogenesis 1985; 6:1577-1583.
10. Lington AW, Bird MG, Plutnick RT, Stubblefield WA, Scala RA. Chronic, toxicity and carcinogenic evaluation of diisononyl phthalate in rats. Fund Appl Toxicol 1997; 36:79-89.
11. Butala JH, Moore MR, Cifone MA. Oncogenicity study of diisononyl phthalate in mice. Toxicologist 1997, 36(1):173.
12. Astill BD, Gingell R, Quest D, Hellwig J, Hodgson JR, Kuettler K, Mellert W, Murphy SR, Sielken RL Jr, Tyler TR. Oncogenicity testing of 2-ethylhexanol in Fischer 344 rats and B6C3F1 mice. Fund Appl Toxicol 1996; 31:29-41.
13. Gold LS, Zeiger E. Handbook of Carcinogenic Potency and Genotoxicity Databases. New York: CRC Press, 1997.
14. Malley LA, Carakostas M, Hansen JF, Rusch GM, Kelley DP, Trochimowicz HJ. Two-year inhalation toxicity study in rats with hydrochorofluorocarbon 123. Fund Appl Toxicol 1995; 25:101-114.
15. Shirasu Y. Oxadiazon - 24 Month Chronic Toxicity and Carcinogenicity Study in Wistar Rats. Tokoyo, Japan: Institute of Environmental Toxicology, 1987, MRID 40993401 (unpublished).
16. Shirasu Y. Oxadiazon - 23 Month Chronic Toxicity and Carcinogenicity Study in ICR-JCL Mice. Tokoyo, Japan: Institute of Environmental Toxicology, 1987, MRID 40993301 (unpublished).
17. Hollander H, Wiegand W. Diclofop methyl-Toxicity and Tumorigenicity Study in Mice during Dietary Administration for 2 Years with Interim Sacrifice After 88 Weeks. Frankfurt, Germany: Prepared by Pharma Research Toxicology and Pathology, 1978, MRID 92036058 (unpublished).
18. EPA. Carcinogenicity Studies of Oxadiazon in Fischer Rat. Nippon Institute for Biological Sciences, Japan (unpublished), EPA accession numbers 256142, 256143, 256144. Washington, DC: Office of Pesticides Program, U.S. Environmental Protection Agency, 1981.
19. EPA. Carcinogenicity Studies of Oxadiazon in CD Mice; Life Sciences Research England, (unpublished). EPA accession numbers 248601, 248602, 248603, 248604, 248605. Washington, DC.: Office of Pesticides Program, U.S. Environmental Protection Agency, 1982.
20. EPA. Lactofen-Mouse-Oncogenicity Study in Mice PPG-844 Technical. Hazelton Laboratories, Vienna, Virginia. EPA Accession No. 073848. Washington, DC: Office of Pesticides Program, U.S. Environmental Protection Agency, 1985.
21. EPA. Diclofop Methyl-Combined Chronic Toxicity (12 and 24 Months) and Carcinogenicity (24 Months) Study in Rats. Hoechst Aktiengesellschaft, D-65926 Frankfurt am Main. Unpublished. EPA Accession No. 43927302. Washington, DC: Office of Pesticides Program, U.S. Environmental Protection Agency, 1996.
22. NTP. Compendium of abstracts from long-term cancer studies reported by the National Toxicology Program from 1976-1992. Enviorn Health Persp 1993, 101 (Suppl 1):1-295.
23. Biegel LB, Hurtt ME, Frame SR, O'Conner JC, Cook J. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol Sci 2001; 60:44-55.
24. Svoboda DJ, Azarnoff DL. Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolidemic drug. Cancer Res 1979; 39:3419-3428.
25. Tucker MJ, Orton TC. Comparative Toxicology of Hypolipidaemic Fibrates. Bristol, PA: Taylor and Francis, 1995.
26. Reddy JK, Rao MS. Transplantable pancreatic carcinoma of the rat. Science 1997; 198:78-80.
27. Reddy JK, Rao MS. Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J Natl Cancer Inst 1997; 59:645-1650.
28. Committee of Principal Investigators. A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 1978; 40:1069-1118.
29. Committee of Principal Investigators. WHO cooperative trial on the primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980; ii:379-385.
30. Committee of Principal Investigators. WHO cooperative trial on the primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984; ii:600-604.
31. IARC. International Agency for Research on Cancer. Some pharmaceutical drugs. Clofibrate, Lyon, France 1996; 66:391-426.
32. Frick MH, Elo O, Heinonen OP, Heinsalmi P, Helo P, Huttenen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary breast disease. New Engl J Med 1987; 317:1237-1245.
33. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650.
34. Corton JC, Lapinskas PJ, Gonzalez FJ. Central role of PPAR in the mechanism of action of hepatocarcinogenic peroxisome proliferators. Mutat Res 2000; 448:139-151.
35. Peters JM, Cattley RC, Gonzalez FJ. Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 1997, 18(11):2029-2033.
36. Marsman DS, Cattley RC, Conway JG, Popp JA. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenesis of the peroxisome proliferators DEHP and Wy-14,643 in rats. Cancer Res 1988; 48:6739-6744.
37. Lake BG, Rumsby PC, Price RJ, Cunninghame ME. Species differences in hepatic roxisome proliferation, cell replication and transforming growth factorbeta1 gene expression in the rat, Syrian hamster and guinea pig. Mutat Res 2000; 448:213-225.
38. Rose ML, Rusyn I, Bojes HK, Belyea J, Cattley RC, Thurman RG. Role of Kupffer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat Res 2000; 448:179-192.
39. Rao MS, Reddy JK. Hepatocarcinogenesis of peroxisome proliferators. Ann NY Acad Sci 1996; 804:573-587.
40. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Reg Toxicol Pharmacol 1998; 27:47-60.
41. Cook JC, Murray SM, Frame SR, Hurtt ME. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol 1992; 113:209-217.
42. Obourn JD, Frame SR, Bell RH Jr, Longnecker DS, Elliott GS, Cook JC. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferators Wy-14,643. Toxicol Appl Pharmacol 1997; 145:425-436.
43. Dekant W, Metzler M, Henschler D. Identification of S-1,2-dichlorovinyl- N-acetylcysteine as a urinary metabolite of trichloroethylene: bioactivation through glutathione-conjugation as a possible explanation of its nephrocarcinogenicity. Biochem Pharmacol 1986; 35:2455-2458.
44. Dekant W, Metzler M, Henschler D. Identification of S-1,2,2- trichlorovinyl-N-cetylcysteine as a urinary metabolite of tetrachloroethylene: bioactivation through glutathione-conjugation as a possible explanation of its nephrocarcinogenicity. J Biochem Toxicol 1986; 1:57-72.
45. Green T, Odum J, Nash JA, Foster JR. Perchloroethylene-induced rat kidney tumors: an investigation of the mechanisms involved and their relevance to humans. Toxicol Appl Pharmacol 1990; 103:77-89.
46. Ashby J, Brady A, Elcombe CR, Elliott BM, Ishmael J, Odum J, Tugwood JD, Kettle S, Purchase IFH. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 1994, 13(Suppl 2):S1-S117.
47. IARC. International Agency for Research on Cancer. Some industrial chemicals, di(2-ethylhexyl)phthalate. Lyon, France 2000; 77:41-148.
48. Van den Heuve JP. Peroxisome proliferator-activated receptor (PPARS) and carcinogenesis. Toxicol Sci 1999; 47:1-8.
49. Cohen SM, Meek ME, Klaunig JE, Patton DE, Fenner-Crisp PA. The human relevance of information on carcinogenic modes of action. Overview 2003; 33:581-589.
50. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 2003; 33:591-653.
51. Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARα agonist-induced rodent tumors: mode of action and human relevance. Crit Rev Toxicol 2003; 33:655-780.
52. Isenberg JS, Kamendulis LM, Ackley DC, Smith JH, Pugh G Jr, Lington AW, McKee RH, Klaunig JE. Reversibility and persistence of di-2-ethylhexyl phthalate and phenobarbital-induced hepatocellular changes in rodents. Toxicol Sci 2001; 64:192-199.
53. PDR, Lopid. In: Physician's Desk Reference. Medical Economics Data, 1993:1787-1790.
54. Scotto C, Keller J-M, Schohn H, Dauca M. Comparative effects of clofibrate on peroxisomal enzymes of human (Hep EBNA2) and rat (FaO) hepatoma cell lines. Euro J Cell Biol 1995; 66:375-381.
55. Walgren JE, Kurtz DT, McMillan JM. Expression of PPARα in human hepatocytes and activation by trichloroacetate and dichloroacetate. Res Commun Mol Pathol Pharmacol 2000; 108:116-131.
56. Just WW, Gorgas K, Hartl F-U, Heinemann P, Salzer M, Schimassek H. Biochemical effects and zonal heterogeneity of peroxisome proliferation induced by perflurocarboxylic acids in rat liver. Hepatology 1989; 9:570-581.
57. Palmer CNA, Hsu M-H, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator-activated receptor alpha expression in human liver. Mol Pharmacol 1998; 53:14-22.
58. Woodyatt NJ, Lambe KG, Myers KA, Tugwood JD, Roberts RA. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 1999; 20:369-372.
59. Sher T, Yi H-F, McBride OW, Gonazalez F. c-DNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator-activated receptor. Biochemistry 1993; 23:5598-5604.
60. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator-activated receptor (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 1994; 51:157-166.
61. Pineau T, Hudgins WR, Liu L, Chen L-C, Sher T, Gonazalez FJ, Samid D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 1996; 52:659-667.
62. Lapinskas PJ, Corton JC. Peroxisome proliferator-activated receptor alpha: central mediator of peroxisome proliferator toxicity. CIIT Activities 1997, 17(1):1-7.